Key Highlights

  • BridgeBio Pharma shares are trading at $65.32 in Wednesday's session, down 5.64%.
  • The company published new peer-reviewed real-world data showing its drug Attruby reduced a composite of clinical worsening events by 34% versus tafamidis.
  • The positive clinical data has failed to offset broader selling pressure over the prior sessions, compounded by continued insider selling from the CEO's trust and a recent secondary offering.
  • Shares remain well below their 52-week high of $90.17 even as Sell-Side analysts hold bullish price targets averaging around $109.

Positive Real-World Data Fails to Offset Selling Pressure

BridgeBio Pharma (NASDAQ:BBIO) shares are extending a multi-week slide in Wednesday's session, falling further despite the company announcing new peer-reviewed real-world data showing its lead drug acoramidis, marketed as Attruby, reduced a composite of clinical worsening events by 34% versus rival tafamidis in patients with transthyretin amyloid cardiomyopathy. The study also found a 43% reduction in risk of diuretic intensification, an early marker of worsening heart failure, with the separation in outcomes emerging within weeks of treatment initiation. Despite the clinical significance of the findings, the news has not been enough to offset broader selling pressure that has knocked roughly 12% off the stock over the prior sessions.

Insider Selling and a Recent Secondary Offering Add Supply

That broader pressure has been compounded by continued insider selling from chief executive Neil Kumar's trust and a recent secondary offering by KKR that added Supply overhang to the stock. BridgeBio Pharma is a commercial-stage biopharmaceutical company headquartered in Palo Alto, California, dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. Its commercial and late-stage pipeline includes Attruby for ATTR-CM and Nulibry for molybdenum cofactor deficiency, alongside programs like Encaleret for hypoparathyroidism-related disorders and BBP-812 gene therapy for Canavan disease.

Analysts Remain Bullish Despite the Pullback

Shares remain well below their 52-week high of $90.17 even as sell-side analysts hold bullish price targets averaging around $109, a gap that suggests the market has not yet caught up to the fundamental case built by the new real-world evidence. The company operates through a decentralized model of Subsidiary companies spanning Mendelian genetic diseases, oncology and gene therapy, backed by licensing arrangements that support its broader pipeline.